
Adjuvant Pertuzumab Plus Trastuzumab and Chemotherapy Leads to OS Benefit in Early-Stage HER2+ Breast Cancer
The addition of adjuvant pertuzumab (Perjeta) to trastuzumab (Herceptin) and chemotherapy led to a significant improvement in overall survival (OS) vs placebo plus trastuzumab and chemotherapy in patients with early-stage, HER2-positive operable breast …